Welcome to our dedicated page for NANALYSIS SCIENTIFIC news (Ticker: NSCIF), a resource for investors and traders seeking the latest updates and insights on NANALYSIS SCIENTIFIC stock.
Nanalysis Scientific Corp. is a leading provider of portable NMR machines and MRI technology for industrial and research applications. The company operates in two primary segments: Scientific Equipment and Security Services. In the Scientific Equipment business, Nanalysis develops and manufactures portable NMR spectrometers for laboratory and industrial markets. Their products are used in various industries and research labs globally. Recently, the company achieved significant revenue growth, introduced new innovative products, and expanded its Security Services business through a multi-million dollar government contract.
Nanalysis Scientific Corp. reported strong growth in Q3 2022, achieving consolidated revenue of $6,878K, a 106% increase from the prior year. The company attributes this growth to an uptick in product sales and ongoing airport security services. Despite a net loss of $(2,599K) for the quarter, financial metrics indicate operational improvements. The company received $1.5 million from a federal funding program to support growth and has consolidated its credit facilities to enhance liquidity. CEO Sean Krakiwsky expressed confidence in future growth, driven by increased demand for its 100 MHz NMR product and the CATSA contract.
Nanalysis Scientific Corp. (TSXV: NSCI, OTCQX: NSCIF) will hold a conference call on November 29, 2022, at 5:00 PM ET to discuss third-quarter results for the period ending September 30, 2022. CEO Sean Krakiwsky and Interim CFO Randall McRae will lead the call. A European Q&A session is scheduled for November 30, 2022, at 8:30 AM ET. Investors can participate through a live webcast or by phone. Nanalysis specializes in portable Nuclear Magnetic Resonance devices for various industries and continues to expand its product lineup.
Nanalysis Scientific Corp. announced preliminary Q3 2022 revenues expected to exceed $6.8 million, marking a year-over-year growth of over 100%. The company is optimistic about recovery in its core NMR business and anticipates significant billings from its CATSA service contract in Q4 2022. Noteworthy achievements this quarter include record shipments of 20 units of the 100MHz NMR and a C$1.1 million contract for a custom MRI system in France. CEO Sean Krakiwsky will present at the LD Micro Conference on Oct. 25.
Nanalysis Scientific Corp. (NSCIF) has granted 377,500 stock options to employees, including 175,000 to an officer, at $1.10 per share, with a five-year exercise period. The options will vest over three years. This move aims to incentivize employees and align their interests with shareholders. Nanalysis specializes in portable Nuclear Magnetic Resonance (NMR) technology for various industries and has an innovation pipeline that includes a new 100MHz device. The company also broadens its market presence through its recent acquisition of K'Prime and a 43% stake in Quad Systems AG.
Nanalysis Scientific Corp. reported its Q2 2022 results, highlighting a 19% revenue growth year-over-year to $5.187 million, despite a net loss of $2.532 million compared to a net income of $222,000 in Q2 2021. The gross margin decreased from 67% to 62%. The company secured a $160 million service contract with CATSA effective May 25, 2022. Due to operational challenges in scaling its NMR sales, the company is restructuring its sales model and focusing on increasing production capabilities. Nanalysis anticipates revenue growth will improve in the current quarter.
Nanalysis Scientific Corp. will hold a conference call on August 25, 2022, at 5:00 PM ET to discuss its second-quarter financial results for the period ending June 30, 2022. CEO Sean Krakiwsky and Interim CFO Randall McRae will lead the discussion. Investors can participate by phone or through a live webcast. A follow-up Q&A session for European investors is scheduled for August 26 at 8:30 AM ET. Nanalysis specializes in portable NMR technology for various industries and recently expanded its product offerings with advanced devices.
Nanalysis Scientific Corp. announced a management transition on July 21, 2022, with CFO Luke Caplette stepping down but remaining as a part-time consultant. Corporate Controller Randall McRae has been appointed as interim CFO. The company appreciates Caplette's contributions and expresses confidence in McRae’s experience and leadership during this transition. McRae brings over 15 years of experience, having worked with MNP LLP/Deloitte LLP and co-founded a cloud accounting firm. Nanalysis focuses on developing portable Nuclear Magnetic Resonance spectrometers for various industries.
Nanalysis Scientific Corp. will participate in two upcoming investment conferences. The first is the LD Micro Conference on June 7, 2022, at 4:30 PM ET, where investors can engage in 1x1 meetings. The second event is the OTCQX Best 50 Virtual Investor Conference on June 16, 2022, at 1:00 PM ET, also featuring virtual 1x1 sessions. Nanalysis specializes in portable NMR technology and aims to enhance investor engagement through these interactive presentations.
Nanalysis Scientific Corp. reported its first-quarter results for 2022, highlighting a consolidated revenue of $5,554K, a 69% increase year-over-year. However, the company faced a net loss of $1,492K, compared to a loss of $467K in the same period last year. The gross margin declined to 60% from 64%. Significant developments included a $160 million multi-year service contract with CATSA and a $4,985,000 funding commitment from the Canadian government.
Nanalysis Scientific Corp. announced a six-year contract valued at $160 million with the Canadian Air Transportation Security Authority (CATSA) to provide service and maintenance for security screening equipment. This contract, effective from May 25, 2022, may be renewed for an additional five years, creating a potential eleven-year recurring revenue opportunity. The project’s phase-in process is underway, targeting completion by the end of Q1 2023. This win is expected to enhance Nanalysis's footprint in the security vertical and contribute to shareholder value.
FAQ
What is the current stock price of NANALYSIS SCIENTIFIC (NSCIF)?
What is the market cap of NANALYSIS SCIENTIFIC (NSCIF)?
What does Nanalysis Scientific Corp. specialize in?
In which industries are Nanalysis products used?
What recent achievements has Nanalysis Scientific Corp. made?
What are the core business segments of Nanalysis?
What sets Nanalysis Scientific Corp. apart in the market?
How can investors participate in Nanalysis updates and calls?
What financial highlights has Nanalysis recently reported?
What is the significance of the recent stock options grant by Nanalysis?
